BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE

By Walenga J.M.   Jeske W.P.   Bara L.   Samama M.M.   Fareed J.  

Thrombosis Research, Vol. 86, Iss. 1, 1997-04 ,pp. : 1-36

Elsevier

Access to resources Recommend Favorite

Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site

By Yu G.   LeBrun L.   Gunay N.S.   Hoppensteadt D.   Walenga J.M.   Fareed J.   Linhardt R.J.  

Thrombosis Research, Vol. 100, Iss. 6, 2000-12 ,pp. : 549-556

Elsevier

Access to resources Recommend Favorite

THE SYNTHETIC PENTASACCHARIDE SR 90107A/ORG 31540 DOES NOT RELEASE LIPASE ACTIVITY INTO THE PLASMA

By Hoffmann P.   Bernat A.   Dumas A.   Petitou M.   Herault J.P.   Herbert J.M.  

Thrombosis Research, Vol. 86, Iss. 4, 1997-05 ,pp. : 325-332

Elsevier

Access to resources Recommend Favorite

DETERMINATION OF THE ANTI-FACTOR Xa ACTIVITY OF THE SYNTHETIC PENTASACCHARIDE SR 90107A/ORG 31540 AND OF TWO STRUCTURAL ANALOGUES

By Lormeau J.C.   Herault J.P.   Gaich C.   Barzu T.   van Dinther T.G.   Visser A.   Herbert J.M.  

Thrombosis Research, Vol. 85, Iss. 1, 1997-01 ,pp. : 67-75

Elsevier

Access to resources Recommend Favorite

Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis

By Decousus Hervé   Rivron-Guillot Karine   Girard Gaelle   Moulin Nathalie  

Future Cardiology, Vol. 1, Iss. 6, 2005-11 ,pp. : 743-758

Future Medicine

Access to resources Recommend Favorite